8-KLeadership ChangesExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (Mar 4, 2011)

Filed March 4, 2011For Securities:BMYCELG-RIBMYMP

Summary

Bristol Myers Squibb Company (BMY) filed an 8-K report on March 3, 2011, detailing a significant change in its Board of Directors. Effective March 1, 2011, the Board elected Elliott Sigal, M.D., Ph.D. as a new member, expanding the Board's size to twelve directors. Dr. Sigal, who has been with the company for over 13 years and currently holds the position of Executive Vice President, Chief Scientific Officer, and President of Research and Development, brings extensive internal expertise to the Board. While Dr. Sigal's appointment strengthens the Board's scientific and research capabilities, it's important for investors to note that he is not considered an independent director due to his ongoing executive role within the company. He will continue his duties in R&D and will serve on the Science and Technology Committee. Dr. Sigal will not receive separate compensation for his board service, aligning with the company's executive compensation structure. His election will be subject to stockholder approval at the upcoming Annual Meeting.

Key Highlights

  • 1Elliott Sigal, M.D., Ph.D., was elected to the Bristol Myers Squibb Board of Directors, effective March 1, 2011.
  • 2The Board's size was increased from eleven to twelve members to accommodate Dr. Sigal's election.
  • 3Dr. Sigal has a long tenure with the company, serving for over 13 years and currently as Executive Vice President, Chief Scientific Officer, and President of Research and Development.
  • 4Due to his executive position, Dr. Sigal is not considered an independent director under NYSE or company standards.
  • 5Dr. Sigal will continue to serve on the Science and Technology Committee of the Board.
  • 6Dr. Sigal will not receive additional compensation for his service as a director.
  • 7Dr. Sigal's election is subject to ratification by stockholders at the Annual Meeting on May 3, 2011.

Frequently Asked Questions

Elliott Sigal, M.D., Ph.D. is a long-serving executive at Bristol Myers Squibb. He has been with the company for over 13 years and currently holds the critical role of Executive Vice President, Chief Scientific Officer, and President of Research and Development. His election to the Board of Directors brings his extensive scientific and R&D leadership experience directly to the governance level.

Dr. Sigal is not considered independent because he is an active employee and executive officer of Bristol Myers Squibb, holding significant operational responsibilities in research and development. Independence standards typically require directors to have no material relationship with the company other than their directorship.

No, Dr. Sigal will not receive separate compensation for his service as a director. His compensation remains tied to his executive role within the company, as per the standard executive compensation program.

Dr. Sigal's election signifies a strengthening of the Board's scientific and R&D oversight. His deep understanding of the company's research pipeline and development strategy can provide valuable insights and guidance to the Board's decision-making processes, potentially impacting the company's innovation and future growth prospects.